$MGTX

MeiraGTx Holdings plc (MGTX): Entry into a Material Definitive Agreement

MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 mgtx-20260630xex10d1.htm EX-10.1 Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. ​ Execution Version ​ ​ ROYALTY NOTE PUR

Original reporting
Published Jul 7, 2026, 11:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 7, 2026, 12:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$MGTX
Neutral
medium confidence
Mentioned
$MGTX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MGTXNeutralMed
01

Why it matters

A royalty note purchase agreement typically ties repayment to future revenues and may be secured, which can affect valuation through cash-flow expectations and covenant/default risk.

02

Market read

This is a primary-source financing disclosure that can influence how investors price MeiraGTx’s liquidity runway and secured-credit risk.

03

What to watch

Traders should verify the actual note size, effective cost (including revenue participation/milestones), collateral scope, and any default/delisting covenants—these drive real risk more than the existence of the agreement.

Relevance 6/10Novelty 5/10Timing: today’s SEC 8-K filing (July 7, 2026)

Background

The 8-K reports entry into a material definitive agreement and related items (termination of another agreement, creation of direct financial obligations, and unregistered equity sales).

Company-level read

Ticker impact

$MGTXNeutralMedium confidence
Context

MeiraGTx Holdings plc filed an 8-K for entry into a material definitive royalty note purchase agreement, creating new direct financial obligations.

Expected impact

Likely modest, with focus on financing terms and any downstream covenant/repayment implications rather than immediate earnings impact.

Evidence & confidence

The 8-K confirms a material definitive agreement and related obligations, but the scraped excerpt does not include key economic terms (size, pricing, repayment/revenue participation) needed to gauge magnitude.

Market effects

Biopharma/biotech issuers may face continued reliance on structured financings (royalty notes), affecting sector-wide risk appetite for non-dilutive vs covenant-heavy capital.

No clear regional spillover indicated by the excerpt.

Limited based on the excerpt; the agreement appears issuer-specific.

Counterpoint

If the royalty note is genuinely non-dilutive and priced favorably, the market may interpret it as reducing financing risk rather than increasing it.

Key entities

  • MeiraGTx Holdings plc

    Subject of the 8-K; entered into a material definitive royalty note purchase agreement and related obligations.

  • Maverick SA LLC

    Named as purchaser agent in the royalty note purchase agreement excerpt.

Related articles

$MGTXMed

MeiraGTx Holdings plc (MGTX): Results of Operations and Financial Condition

MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MeiraGTx Reports Second Quarter 2026 Financial and Operational Results - Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe

$MGTXMedAI 8/10

MeiraGTx secures $400m from Oberland Capital

MeiraGTx said it will receive up to $375m in non-dilutive capital from Oberland Capital via capped royalties, plus up to $25m in equity. An initial $135m was funded, including $125m in low single-digit royalties and a $10m equity stake. Additional payments total $150m tied to Phase II completion and regulatory approvals for AAV2-hAQP1 and bota-vec.

$MGTXMedAI 8/10

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx Holdings (Nasdaq: MGTX) said it agreed with Oberland Capital for up to $400m to fund development/commercialization of AAV2-hAQP1 (RIX), bota-vec (XLRP) and AAV-AIPL1. Oberland will provide up to $375m in non-dilutive capped royalty funding and up to $25m equity, with additional tranches tied to 2027–2028 data/approvals.

$OTEXHighAI 8/10

OPEN TEXT CORP (OTEX): Other Events

OPEN TEXT CORP (OTEX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 OpenText Announces Senior Secured Notes Offering to Redeem its Outstanding 2027 Notes and Fund Tender Offer for a Portion of its Outstanding 2028 Notes Waterloo, ON, September 23, 2026 – Open Text Corporation (the “Company” or “OpenText”) (NASDAQ: OTEX), (TSX: OTEX)

$BCDAMed

BioCardia, Inc. (BCDA): Other Events

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission SUNNYVALE, Calif. – September 23, 2026 – BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of ca

$CLow

Citigroup Announces €1.5 Billion Redemption of 0.500% Fixed Rate / Floating Rate Notes Due 2027

Citigroup Inc. announced the redemption of €1.5 billion of its 0.500% Fixed Rate/Floating Rate Notes due 2027. The redemption date is October 8, 2026, with the cash redemption price equal to par plus accrued interest. This move aligns with Citigroup's liability management strategy to optimize funding and capital structure. Citibank, N.A. serves as the paying agent for the notes.